Home > Haematology > EHA 2019 > Myeloid Malignancies > Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia

Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia

Presented By
Prof. Jorge Cortes, University of Texas MD Anderson Cancer Center, USA
Conference
EHA 2020
Trial
Phase 1
In a phase 1 trial of asciminib in combination with imatinib in heavily pre-treated patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP), 60% (9/15) of participants achieved a molecular response rate <1% in the asciminib+imatinib arm [1]. Asciminib binds the myristate-binding pocket of the Bcr-Abl kinase domain. In the current study, presented by Prof. Jorge Cortes (University of Texas MD Anderson Cancer Center, USA), patients ≥18 years of age had a confirmed diagnosis of CML-CP. Patients had to be on a minimum of 2 years treatment with imatinib first line for CML-CP, BCR-ABL1 levels had to be >0.01% International Scale (IS) and ≤ 1% IS at the time of study entry as confirmed with a central assessment at screening and must not have achieved molecular response (MR)4 IS at any time during prior imatinib treatmen...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on